Key Focus for Regencell Bioscience Investors

By Susan Ramirez • Thursday, August 28 15:23 • Permanent Link

Regencell Bioscience marked a 14.1% change today, compared to 0.0% for the S&P 500. Is it a good value at today's price of $16.25? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong.
Regencell Bioscience belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 22.94 and an average price to book (P/B) of 3.19
The company's P/B ratio is 1160.82
Regencell Bioscience has a trailing 12 month Price to Earnings (P/E) ratio of -1625.1 based on its trailing 12 month price to earnings (EPS) of $-0.01 per share
Over the last four years, Regencell Bioscience has averaged free cash flows of $-2841341.0, which on average grew -59.3%
Regencell Bioscience has moved 7394.7% over the last year compared to 15.9% for the S&P 500 -- a difference of 7378.8%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.